Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Drug Metabolism & Disposition
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Drug Metabolism & Disposition

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit dmd on Facebook
  • Follow dmd on Twitter
  • Follow ASPET on LinkedIn

Index by author

November 01, 1994; Volume 22,Issue 6
  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z

A

  1. Alton, K B

    1. You have access
      Urinary metabolites of (R),(R)-labetalol.
      K B Alton, T M Chan and B N Pramanik
      Drug Metabolism and Disposition November 1994, 22 (6) 866-872;
  2. Anders, M W

    1. You have access
      Tissue distribution and stereoselectivity of remacemide-glycine hydrolase.
      H Heyn, Y G Bankmann and M W Anders
      Drug Metabolism and Disposition November 1994, 22 (6) 973-974;
  3. Ardouin, T

    1. You have access
      Pharmcokinetics in healthy volunteers and patients of NAc-SDKP (seraspenide), a negative regulator of hematopoiesis.
      E Ezan, P Carde, J Le Kerneau, T Ardouin, F Thomas, F Isnard, E Deschamps de Paillette and J M Grognet
      Drug Metabolism and Disposition November 1994, 22 (6) 843-848;

B

  1. Babu, S R

    1. You have access
      Glucuronidation of N-acetylbenzidine by human liver.
      S R Babu, V M Lakshmi, T V Zenser and B B Davis
      Drug Metabolism and Disposition November 1994, 22 (6) 922-927;
  2. Bankmann, Y G

    1. You have access
      Tissue distribution and stereoselectivity of remacemide-glycine hydrolase.
      H Heyn, Y G Bankmann and M W Anders
      Drug Metabolism and Disposition November 1994, 22 (6) 973-974;
  3. Barnett, J L

    1. You have access
      Interpatient heterogeneity in expression of CYP3A4 and CYP3A5 in small bowel. Lack of prediction by the erythromycin breath test.
      K S Lown, J C Kolars, K E Thummel, J L Barnett, K L Kunze, S A Wrighton and P B Watkins
      Drug Metabolism and Disposition November 1994, 22 (6) 947-955;
  4. Boelsterli, U A

    1. You have access
      Mechanism of covalent adduct formation of diclofenac to rat hepatic microsomal proteins. Retention of the glucuronic acid moiety in the adduct.
      A Kretz-Rommel and U A Boelsterli
      Drug Metabolism and Disposition November 1994, 22 (6) 956-961;
  5. Bonner, H S

    1. You have access
      Metabolic pathways of WR-2721 (ethyol, amifostine) in the BALB/c mouse.
      L M Shaw, H S Bonner and D Q Brown
      Drug Metabolism and Disposition November 1994, 22 (6) 895-902;
  6. Boyd, S A

    1. You have access
      The orally active renin inhibitor A-74273. In vivo and in vitro morpholine ring metabolism in rats, dogs, and humans.
      J F Denissen, B A Grabowski, M K Johnson, S A Boyd, J T Uchic, H Stein, S Cepa and P Hill
      Drug Metabolism and Disposition November 1994, 22 (6) 880-888;
  7. Brennan, J M

    1. You have access
      Stereoselective pharmacokinetics of L-buthionine SR-sulfoximine in patients with cancer.
      F P Lacreta, J M Brennan, T C Hamilton, R F Ozols and P J O'Dwyer
      Drug Metabolism and Disposition November 1994, 22 (6) 835-842;
  8. Brown, D Q

    1. You have access
      Metabolic pathways of WR-2721 (ethyol, amifostine) in the BALB/c mouse.
      L M Shaw, H S Bonner and D Q Brown
      Drug Metabolism and Disposition November 1994, 22 (6) 895-902;
  9. Brown, R P

    1. You have access
      A comprehensive evaluation of the vial equilibration method for quantification of the metabolism of volatile organic chemicals. Trichloroethylene.
      C Kim, R O Manning, R P Brown and J V Bruckner
      Drug Metabolism and Disposition November 1994, 22 (6) 858-865;
  10. Bruckner, J V

    1. You have access
      A comprehensive evaluation of the vial equilibration method for quantification of the metabolism of volatile organic chemicals. Trichloroethylene.
      C Kim, R O Manning, R P Brown and J V Bruckner
      Drug Metabolism and Disposition November 1994, 22 (6) 858-865;

C

  1. Carde, P

    1. You have access
      Pharmcokinetics in healthy volunteers and patients of NAc-SDKP (seraspenide), a negative regulator of hematopoiesis.
      E Ezan, P Carde, J Le Kerneau, T Ardouin, F Thomas, F Isnard, E Deschamps de Paillette and J M Grognet
      Drug Metabolism and Disposition November 1994, 22 (6) 843-848;
  2. Cepa, S

    1. You have access
      The orally active renin inhibitor A-74273. In vivo and in vitro morpholine ring metabolism in rats, dogs, and humans.
      J F Denissen, B A Grabowski, M K Johnson, S A Boyd, J T Uchic, H Stein, S Cepa and P Hill
      Drug Metabolism and Disposition November 1994, 22 (6) 880-888;
  3. Chan, T M

    1. You have access
      Urinary metabolites of (R),(R)-labetalol.
      K B Alton, T M Chan and B N Pramanik
      Drug Metabolism and Disposition November 1994, 22 (6) 866-872;
  4. Chauret, N

    1. You have access
      Increased cosedimentation of cytosolic glutathione S-transferases with microsomal fractions prepared from frozen rat liver.
      A E Cribb, G P Griffin, S P Spielberg, T H Rushmore, N Chauret and D A Nicoll-Griffith
      Drug Metabolism and Disposition November 1994, 22 (6) 969-972;
  5. Coddington, A B

    1. You have access
      Hepatic metabolism of spironolactone. Production of 3-hydroxy-thiomethyl metabolites.
      L E Los, S M Pitzenberger, H G Ramjit, A B Coddington and H D Colby
      Drug Metabolism and Disposition November 1994, 22 (6) 903-908;
  6. Colby, H D

    1. You have access
      Hepatic metabolism of spironolactone. Production of 3-hydroxy-thiomethyl metabolites.
      L E Los, S M Pitzenberger, H G Ramjit, A B Coddington and H D Colby
      Drug Metabolism and Disposition November 1994, 22 (6) 903-908;
  7. Crawford, K

    1. You have access
      Terfenadine metabolism in human liver. In vitro inhibition by macrolide antibiotics and azole antifungals.
      M Jurima-Romet, K Crawford, T Cyr and T Inaba
      Drug Metabolism and Disposition November 1994, 22 (6) 849-857;
  8. Cribb, A E

    1. You have access
      Increased cosedimentation of cytosolic glutathione S-transferases with microsomal fractions prepared from frozen rat liver.
      A E Cribb, G P Griffin, S P Spielberg, T H Rushmore, N Chauret and D A Nicoll-Griffith
      Drug Metabolism and Disposition November 1994, 22 (6) 969-972;
  9. Cyr, T

    1. You have access
      Terfenadine metabolism in human liver. In vitro inhibition by macrolide antibiotics and azole antifungals.
      M Jurima-Romet, K Crawford, T Cyr and T Inaba
      Drug Metabolism and Disposition November 1994, 22 (6) 849-857;

D

  1. Davis, B B

    1. You have access
      Glucuronidation of N-acetylbenzidine by human liver.
      S R Babu, V M Lakshmi, T V Zenser and B B Davis
      Drug Metabolism and Disposition November 1994, 22 (6) 922-927;
  2. Dehal, S S

    1. You have access
      Metabolism of the proestrogenic pesticide methoxychlor by hepatic P450 monooxygenases in rats and humans. Dual pathways involving novel ortho ring-hydroxylation by CYP2B.
      S S Dehal and D Kupfer
      Drug Metabolism and Disposition November 1994, 22 (6) 937-946;
  3. Denissen, J F

    1. You have access
      The orally active renin inhibitor A-74273. In vivo and in vitro morpholine ring metabolism in rats, dogs, and humans.
      J F Denissen, B A Grabowski, M K Johnson, S A Boyd, J T Uchic, H Stein, S Cepa and P Hill
      Drug Metabolism and Disposition November 1994, 22 (6) 880-888;
  4. Deschamps de Paillette, E

    1. You have access
      Pharmcokinetics in healthy volunteers and patients of NAc-SDKP (seraspenide), a negative regulator of hematopoiesis.
      E Ezan, P Carde, J Le Kerneau, T Ardouin, F Thomas, F Isnard, E Deschamps de Paillette and J M Grognet
      Drug Metabolism and Disposition November 1994, 22 (6) 843-848;

E

  1. Ehlers, K

    1. You have access
      Identification of 9,13-dicis-retinoic acid as a major plasma metabolite of 9-cis-retinoic acid and limited transfer of 9-cis-retinoic acid and 9,13-dicis-retinoic acid to the mouse and rat embryos.
      G Tzimas, J O Sass, W Wittfoht, M M Elmazar, K Ehlers and H Nau
      Drug Metabolism and Disposition November 1994, 22 (6) 928-936;
  2. Elmazar, M M

    1. You have access
      Identification of 9,13-dicis-retinoic acid as a major plasma metabolite of 9-cis-retinoic acid and limited transfer of 9-cis-retinoic acid and 9,13-dicis-retinoic acid to the mouse and rat embryos.
      G Tzimas, J O Sass, W Wittfoht, M M Elmazar, K Ehlers and H Nau
      Drug Metabolism and Disposition November 1994, 22 (6) 928-936;
  3. Ezan, E

    1. You have access
      Pharmcokinetics in healthy volunteers and patients of NAc-SDKP (seraspenide), a negative regulator of hematopoiesis.
      E Ezan, P Carde, J Le Kerneau, T Ardouin, F Thomas, F Isnard, E Deschamps de Paillette and J M Grognet
      Drug Metabolism and Disposition November 1994, 22 (6) 843-848;

G

  1. Grabowski, B A

    1. You have access
      The orally active renin inhibitor A-74273. In vivo and in vitro morpholine ring metabolism in rats, dogs, and humans.
      J F Denissen, B A Grabowski, M K Johnson, S A Boyd, J T Uchic, H Stein, S Cepa and P Hill
      Drug Metabolism and Disposition November 1994, 22 (6) 880-888;
  2. Griffin, G P

    1. You have access
      Increased cosedimentation of cytosolic glutathione S-transferases with microsomal fractions prepared from frozen rat liver.
      A E Cribb, G P Griffin, S P Spielberg, T H Rushmore, N Chauret and D A Nicoll-Griffith
      Drug Metabolism and Disposition November 1994, 22 (6) 969-972;
  3. Grognet, J M

    1. You have access
      Pharmcokinetics in healthy volunteers and patients of NAc-SDKP (seraspenide), a negative regulator of hematopoiesis.
      E Ezan, P Carde, J Le Kerneau, T Ardouin, F Thomas, F Isnard, E Deschamps de Paillette and J M Grognet
      Drug Metabolism and Disposition November 1994, 22 (6) 843-848;

H

  1. Hall, S D

    1. You have access
      Relationships between the levels of cytochrome P4502C9 and its prototypic catalytic activities in human liver microsomes.
      S D Hall, M A Hamman, A E Rettie, L C Wienkers, W F Trager, M Vandenbranden and S A Wrighton
      Drug Metabolism and Disposition November 1994, 22 (6) 975-978;
  2. Hamilton, T C

    1. You have access
      Stereoselective pharmacokinetics of L-buthionine SR-sulfoximine in patients with cancer.
      F P Lacreta, J M Brennan, T C Hamilton, R F Ozols and P J O'Dwyer
      Drug Metabolism and Disposition November 1994, 22 (6) 835-842;
  3. Hamman, M A

    1. You have access
      Relationships between the levels of cytochrome P4502C9 and its prototypic catalytic activities in human liver microsomes.
      S D Hall, M A Hamman, A E Rettie, L C Wienkers, W F Trager, M Vandenbranden and S A Wrighton
      Drug Metabolism and Disposition November 1994, 22 (6) 975-978;
  4. Hara, K

    1. You have access
      In vitro metabolism of dorzolamide, a novel potent carbonic anhydrase inhibitor, in rat liver microsomes.
      T Hasegawa, K Hara, T Kenmochi and S Hata
      Drug Metabolism and Disposition November 1994, 22 (6) 916-921;
  5. Hasegawa, T

    1. You have access
      In vitro metabolism of dorzolamide, a novel potent carbonic anhydrase inhibitor, in rat liver microsomes.
      T Hasegawa, K Hara, T Kenmochi and S Hata
      Drug Metabolism and Disposition November 1994, 22 (6) 916-921;
  6. Hata, S

    1. You have access
      In vitro metabolism of dorzolamide, a novel potent carbonic anhydrase inhibitor, in rat liver microsomes.
      T Hasegawa, K Hara, T Kenmochi and S Hata
      Drug Metabolism and Disposition November 1994, 22 (6) 916-921;
  7. Heyn, H

    1. You have access
      Tissue distribution and stereoselectivity of remacemide-glycine hydrolase.
      H Heyn, Y G Bankmann and M W Anders
      Drug Metabolism and Disposition November 1994, 22 (6) 973-974;
  8. Hill, P

    1. You have access
      The orally active renin inhibitor A-74273. In vivo and in vitro morpholine ring metabolism in rats, dogs, and humans.
      J F Denissen, B A Grabowski, M K Johnson, S A Boyd, J T Uchic, H Stein, S Cepa and P Hill
      Drug Metabolism and Disposition November 1994, 22 (6) 880-888;
  9. Hirata, K

    1. You have access
      Species differences in the induction of hepatic microsomal carboxylesterases caused by dietary exposure to di(2-ethylhexyl)phthalate, a peroxisome proliferator.
      M Hosokawa, K Hirata, F Nakata, T Suga and T Satoh
      Drug Metabolism and Disposition November 1994, 22 (6) 889-894;
  10. Horie, T

    1. You have access
      Cytochrome P450 isozymes involved in propranolol metabolism in human liver microsomes. The role of CYP2D6 as ring-hydroxylase and CYP1A2 as N-desisopropylase.
      Y Masubuchi, S Hosokawa, T Horie, T Suzuki, S Ohmori, M Kitada and S Narimatsu
      Drug Metabolism and Disposition November 1994, 22 (6) 909-915;
  11. Hosokawa, M

    1. You have access
      Species differences in the induction of hepatic microsomal carboxylesterases caused by dietary exposure to di(2-ethylhexyl)phthalate, a peroxisome proliferator.
      M Hosokawa, K Hirata, F Nakata, T Suga and T Satoh
      Drug Metabolism and Disposition November 1994, 22 (6) 889-894;
  12. Hosokawa, S

    1. You have access
      Cytochrome P450 isozymes involved in propranolol metabolism in human liver microsomes. The role of CYP2D6 as ring-hydroxylase and CYP1A2 as N-desisopropylase.
      Y Masubuchi, S Hosokawa, T Horie, T Suzuki, S Ohmori, M Kitada and S Narimatsu
      Drug Metabolism and Disposition November 1994, 22 (6) 909-915;

I

  1. Inaba, T

    1. You have access
      Terfenadine metabolism in human liver. In vitro inhibition by macrolide antibiotics and azole antifungals.
      M Jurima-Romet, K Crawford, T Cyr and T Inaba
      Drug Metabolism and Disposition November 1994, 22 (6) 849-857;
  2. Isnard, F

    1. You have access
      Pharmcokinetics in healthy volunteers and patients of NAc-SDKP (seraspenide), a negative regulator of hematopoiesis.
      E Ezan, P Carde, J Le Kerneau, T Ardouin, F Thomas, F Isnard, E Deschamps de Paillette and J M Grognet
      Drug Metabolism and Disposition November 1994, 22 (6) 843-848;

J

  1. Jackson, B J

    1. You have access
      Theophylline N-demethylations as probes for P4501A1 and P4501A2.
      M A Sarkar and B J Jackson
      Drug Metabolism and Disposition November 1994, 22 (6) 827-834;
  2. Johnson, M K

    1. You have access
      The orally active renin inhibitor A-74273. In vivo and in vitro morpholine ring metabolism in rats, dogs, and humans.
      J F Denissen, B A Grabowski, M K Johnson, S A Boyd, J T Uchic, H Stein, S Cepa and P Hill
      Drug Metabolism and Disposition November 1994, 22 (6) 880-888;
  3. Jurima-Romet, M

    1. You have access
      Terfenadine metabolism in human liver. In vitro inhibition by macrolide antibiotics and azole antifungals.
      M Jurima-Romet, K Crawford, T Cyr and T Inaba
      Drug Metabolism and Disposition November 1994, 22 (6) 849-857;

K

  1. Kenmochi, T

    1. You have access
      In vitro metabolism of dorzolamide, a novel potent carbonic anhydrase inhibitor, in rat liver microsomes.
      T Hasegawa, K Hara, T Kenmochi and S Hata
      Drug Metabolism and Disposition November 1994, 22 (6) 916-921;
  2. Kim, C

    1. You have access
      A comprehensive evaluation of the vial equilibration method for quantification of the metabolism of volatile organic chemicals. Trichloroethylene.
      C Kim, R O Manning, R P Brown and J V Bruckner
      Drug Metabolism and Disposition November 1994, 22 (6) 858-865;
  3. Kitada, M

    1. You have access
      Cytochrome P450 isozymes involved in propranolol metabolism in human liver microsomes. The role of CYP2D6 as ring-hydroxylase and CYP1A2 as N-desisopropylase.
      Y Masubuchi, S Hosokawa, T Horie, T Suzuki, S Ohmori, M Kitada and S Narimatsu
      Drug Metabolism and Disposition November 1994, 22 (6) 909-915;
  4. Kolars, J C

    1. You have access
      Interpatient heterogeneity in expression of CYP3A4 and CYP3A5 in small bowel. Lack of prediction by the erythromycin breath test.
      K S Lown, J C Kolars, K E Thummel, J L Barnett, K L Kunze, S A Wrighton and P B Watkins
      Drug Metabolism and Disposition November 1994, 22 (6) 947-955;
  5. Kretz-Rommel, A

    1. You have access
      Mechanism of covalent adduct formation of diclofenac to rat hepatic microsomal proteins. Retention of the glucuronic acid moiety in the adduct.
      A Kretz-Rommel and U A Boelsterli
      Drug Metabolism and Disposition November 1994, 22 (6) 956-961;
  6. Kunze, K L

    1. You have access
      Interpatient heterogeneity in expression of CYP3A4 and CYP3A5 in small bowel. Lack of prediction by the erythromycin breath test.
      K S Lown, J C Kolars, K E Thummel, J L Barnett, K L Kunze, S A Wrighton and P B Watkins
      Drug Metabolism and Disposition November 1994, 22 (6) 947-955;
  7. Kupfer, D

    1. You have access
      Metabolism of the proestrogenic pesticide methoxychlor by hepatic P450 monooxygenases in rats and humans. Dual pathways involving novel ortho ring-hydroxylation by CYP2B.
      S S Dehal and D Kupfer
      Drug Metabolism and Disposition November 1994, 22 (6) 937-946;

L

  1. Lacreta, F P

    1. You have access
      Stereoselective pharmacokinetics of L-buthionine SR-sulfoximine in patients with cancer.
      F P Lacreta, J M Brennan, T C Hamilton, R F Ozols and P J O'Dwyer
      Drug Metabolism and Disposition November 1994, 22 (6) 835-842;
  2. Lakshmi, V M

    1. You have access
      Glucuronidation of N-acetylbenzidine by human liver.
      S R Babu, V M Lakshmi, T V Zenser and B B Davis
      Drug Metabolism and Disposition November 1994, 22 (6) 922-927;
  3. Lee, C

    1. You have access
      Identification of hepatocytes as the major locus of 2,3,7,8-tetrachlorodibenzo-p-dioxin-induced CYP1-related P450s, TCDDAA and TCDDAHH, in chick embryo liver.
      L Paroli, C Lee and A B Rifkind
      Drug Metabolism and Disposition November 1994, 22 (6) 962-968;
  4. Le Kerneau, J

    1. You have access
      Pharmcokinetics in healthy volunteers and patients of NAc-SDKP (seraspenide), a negative regulator of hematopoiesis.
      E Ezan, P Carde, J Le Kerneau, T Ardouin, F Thomas, F Isnard, E Deschamps de Paillette and J M Grognet
      Drug Metabolism and Disposition November 1994, 22 (6) 843-848;
  5. Linhart, I

    1. You have access
      Solvolysis of butadiene monoxide.
      I Linhart
      Drug Metabolism and Disposition November 1994, 22 (6) 820-821;
  6. Los, L E

    1. You have access
      Hepatic metabolism of spironolactone. Production of 3-hydroxy-thiomethyl metabolites.
      L E Los, S M Pitzenberger, H G Ramjit, A B Coddington and H D Colby
      Drug Metabolism and Disposition November 1994, 22 (6) 903-908;
  7. Lown, K S

    1. You have access
      Interpatient heterogeneity in expression of CYP3A4 and CYP3A5 in small bowel. Lack of prediction by the erythromycin breath test.
      K S Lown, J C Kolars, K E Thummel, J L Barnett, K L Kunze, S A Wrighton and P B Watkins
      Drug Metabolism and Disposition November 1994, 22 (6) 947-955;

M

  1. Mangold, J B

    1. You have access
      Pharmacokinetics and metabolism of cyclosporin G in humans.
      J B Mangold, H F Schran and F L Tse
      Drug Metabolism and Disposition November 1994, 22 (6) 873-879;
  2. Manning, R O

    1. You have access
      A comprehensive evaluation of the vial equilibration method for quantification of the metabolism of volatile organic chemicals. Trichloroethylene.
      C Kim, R O Manning, R P Brown and J V Bruckner
      Drug Metabolism and Disposition November 1994, 22 (6) 858-865;
  3. Masubuchi, Y

    1. You have access
      Cytochrome P450 isozymes involved in propranolol metabolism in human liver microsomes. The role of CYP2D6 as ring-hydroxylase and CYP1A2 as N-desisopropylase.
      Y Masubuchi, S Hosokawa, T Horie, T Suzuki, S Ohmori, M Kitada and S Narimatsu
      Drug Metabolism and Disposition November 1994, 22 (6) 909-915;

N

  1. Nakata, F

    1. You have access
      Species differences in the induction of hepatic microsomal carboxylesterases caused by dietary exposure to di(2-ethylhexyl)phthalate, a peroxisome proliferator.
      M Hosokawa, K Hirata, F Nakata, T Suga and T Satoh
      Drug Metabolism and Disposition November 1994, 22 (6) 889-894;
  2. Narimatsu, S

    1. You have access
      Cytochrome P450 isozymes involved in propranolol metabolism in human liver microsomes. The role of CYP2D6 as ring-hydroxylase and CYP1A2 as N-desisopropylase.
      Y Masubuchi, S Hosokawa, T Horie, T Suzuki, S Ohmori, M Kitada and S Narimatsu
      Drug Metabolism and Disposition November 1994, 22 (6) 909-915;
  3. Nau, H

    1. You have access
      Identification of 9,13-dicis-retinoic acid as a major plasma metabolite of 9-cis-retinoic acid and limited transfer of 9-cis-retinoic acid and 9,13-dicis-retinoic acid to the mouse and rat embryos.
      G Tzimas, J O Sass, W Wittfoht, M M Elmazar, K Ehlers and H Nau
      Drug Metabolism and Disposition November 1994, 22 (6) 928-936;
  4. Nicoll-Griffith, D A

    1. You have access
      Increased cosedimentation of cytosolic glutathione S-transferases with microsomal fractions prepared from frozen rat liver.
      A E Cribb, G P Griffin, S P Spielberg, T H Rushmore, N Chauret and D A Nicoll-Griffith
      Drug Metabolism and Disposition November 1994, 22 (6) 969-972;

O

  1. O'Dwyer, P J

    1. You have access
      Stereoselective pharmacokinetics of L-buthionine SR-sulfoximine in patients with cancer.
      F P Lacreta, J M Brennan, T C Hamilton, R F Ozols and P J O'Dwyer
      Drug Metabolism and Disposition November 1994, 22 (6) 835-842;
  2. Ohmori, S

    1. You have access
      Cytochrome P450 isozymes involved in propranolol metabolism in human liver microsomes. The role of CYP2D6 as ring-hydroxylase and CYP1A2 as N-desisopropylase.
      Y Masubuchi, S Hosokawa, T Horie, T Suzuki, S Ohmori, M Kitada and S Narimatsu
      Drug Metabolism and Disposition November 1994, 22 (6) 909-915;
  3. Ozols, R F

    1. You have access
      Stereoselective pharmacokinetics of L-buthionine SR-sulfoximine in patients with cancer.
      F P Lacreta, J M Brennan, T C Hamilton, R F Ozols and P J O'Dwyer
      Drug Metabolism and Disposition November 1994, 22 (6) 835-842;

P

  1. Paroli, L

    1. You have access
      Identification of hepatocytes as the major locus of 2,3,7,8-tetrachlorodibenzo-p-dioxin-induced CYP1-related P450s, TCDDAA and TCDDAHH, in chick embryo liver.
      L Paroli, C Lee and A B Rifkind
      Drug Metabolism and Disposition November 1994, 22 (6) 962-968;
  2. Pitzenberger, S M

    1. You have access
      Hepatic metabolism of spironolactone. Production of 3-hydroxy-thiomethyl metabolites.
      L E Los, S M Pitzenberger, H G Ramjit, A B Coddington and H D Colby
      Drug Metabolism and Disposition November 1994, 22 (6) 903-908;
  3. Pramanik, B N

    1. You have access
      Urinary metabolites of (R),(R)-labetalol.
      K B Alton, T M Chan and B N Pramanik
      Drug Metabolism and Disposition November 1994, 22 (6) 866-872;

R

  1. Ramjit, H G

    1. You have access
      Hepatic metabolism of spironolactone. Production of 3-hydroxy-thiomethyl metabolites.
      L E Los, S M Pitzenberger, H G Ramjit, A B Coddington and H D Colby
      Drug Metabolism and Disposition November 1994, 22 (6) 903-908;
  2. Rettie, A E

    1. You have access
      Relationships between the levels of cytochrome P4502C9 and its prototypic catalytic activities in human liver microsomes.
      S D Hall, M A Hamman, A E Rettie, L C Wienkers, W F Trager, M Vandenbranden and S A Wrighton
      Drug Metabolism and Disposition November 1994, 22 (6) 975-978;
  3. Rifkind, A B

    1. You have access
      Identification of hepatocytes as the major locus of 2,3,7,8-tetrachlorodibenzo-p-dioxin-induced CYP1-related P450s, TCDDAA and TCDDAHH, in chick embryo liver.
      L Paroli, C Lee and A B Rifkind
      Drug Metabolism and Disposition November 1994, 22 (6) 962-968;
  4. Rushmore, T H

    1. You have access
      Increased cosedimentation of cytosolic glutathione S-transferases with microsomal fractions prepared from frozen rat liver.
      A E Cribb, G P Griffin, S P Spielberg, T H Rushmore, N Chauret and D A Nicoll-Griffith
      Drug Metabolism and Disposition November 1994, 22 (6) 969-972;

S

  1. Sarkar, M A

    1. You have access
      Theophylline N-demethylations as probes for P4501A1 and P4501A2.
      M A Sarkar and B J Jackson
      Drug Metabolism and Disposition November 1994, 22 (6) 827-834;
  2. Sass, J O

    1. You have access
      Identification of 9,13-dicis-retinoic acid as a major plasma metabolite of 9-cis-retinoic acid and limited transfer of 9-cis-retinoic acid and 9,13-dicis-retinoic acid to the mouse and rat embryos.
      G Tzimas, J O Sass, W Wittfoht, M M Elmazar, K Ehlers and H Nau
      Drug Metabolism and Disposition November 1994, 22 (6) 928-936;
  3. Satoh, T

    1. You have access
      Species differences in the induction of hepatic microsomal carboxylesterases caused by dietary exposure to di(2-ethylhexyl)phthalate, a peroxisome proliferator.
      M Hosokawa, K Hirata, F Nakata, T Suga and T Satoh
      Drug Metabolism and Disposition November 1994, 22 (6) 889-894;
  4. Schran, H F

    1. You have access
      Pharmacokinetics and metabolism of cyclosporin G in humans.
      J B Mangold, H F Schran and F L Tse
      Drug Metabolism and Disposition November 1994, 22 (6) 873-879;
  5. Semple, H A

    1. You have access
      Propranolol disposition in the single-pass isolated, perfused rat liver in the presence and absence of insulin and glucagon.
      H A Semple and F Xia
      Drug Metabolism and Disposition November 1994, 22 (6) 822-826;
  6. Shaw, L M

    1. You have access
      Metabolic pathways of WR-2721 (ethyol, amifostine) in the BALB/c mouse.
      L M Shaw, H S Bonner and D Q Brown
      Drug Metabolism and Disposition November 1994, 22 (6) 895-902;
  7. Spielberg, S P

    1. You have access
      Increased cosedimentation of cytosolic glutathione S-transferases with microsomal fractions prepared from frozen rat liver.
      A E Cribb, G P Griffin, S P Spielberg, T H Rushmore, N Chauret and D A Nicoll-Griffith
      Drug Metabolism and Disposition November 1994, 22 (6) 969-972;
  8. Stein, H

    1. You have access
      The orally active renin inhibitor A-74273. In vivo and in vitro morpholine ring metabolism in rats, dogs, and humans.
      J F Denissen, B A Grabowski, M K Johnson, S A Boyd, J T Uchic, H Stein, S Cepa and P Hill
      Drug Metabolism and Disposition November 1994, 22 (6) 880-888;
  9. Suga, T

    1. You have access
      Species differences in the induction of hepatic microsomal carboxylesterases caused by dietary exposure to di(2-ethylhexyl)phthalate, a peroxisome proliferator.
      M Hosokawa, K Hirata, F Nakata, T Suga and T Satoh
      Drug Metabolism and Disposition November 1994, 22 (6) 889-894;
  10. Suzuki, T

    1. You have access
      Cytochrome P450 isozymes involved in propranolol metabolism in human liver microsomes. The role of CYP2D6 as ring-hydroxylase and CYP1A2 as N-desisopropylase.
      Y Masubuchi, S Hosokawa, T Horie, T Suzuki, S Ohmori, M Kitada and S Narimatsu
      Drug Metabolism and Disposition November 1994, 22 (6) 909-915;

T

  1. Thomas, F

    1. You have access
      Pharmcokinetics in healthy volunteers and patients of NAc-SDKP (seraspenide), a negative regulator of hematopoiesis.
      E Ezan, P Carde, J Le Kerneau, T Ardouin, F Thomas, F Isnard, E Deschamps de Paillette and J M Grognet
      Drug Metabolism and Disposition November 1994, 22 (6) 843-848;
  2. Thummel, K E

    1. You have access
      Interpatient heterogeneity in expression of CYP3A4 and CYP3A5 in small bowel. Lack of prediction by the erythromycin breath test.
      K S Lown, J C Kolars, K E Thummel, J L Barnett, K L Kunze, S A Wrighton and P B Watkins
      Drug Metabolism and Disposition November 1994, 22 (6) 947-955;
  3. Trager, W F

    1. You have access
      Relationships between the levels of cytochrome P4502C9 and its prototypic catalytic activities in human liver microsomes.
      S D Hall, M A Hamman, A E Rettie, L C Wienkers, W F Trager, M Vandenbranden and S A Wrighton
      Drug Metabolism and Disposition November 1994, 22 (6) 975-978;
  4. Tse, F L

    1. You have access
      Pharmacokinetics and metabolism of cyclosporin G in humans.
      J B Mangold, H F Schran and F L Tse
      Drug Metabolism and Disposition November 1994, 22 (6) 873-879;
  5. Tzimas, G

    1. You have access
      Identification of 9,13-dicis-retinoic acid as a major plasma metabolite of 9-cis-retinoic acid and limited transfer of 9-cis-retinoic acid and 9,13-dicis-retinoic acid to the mouse and rat embryos.
      G Tzimas, J O Sass, W Wittfoht, M M Elmazar, K Ehlers and H Nau
      Drug Metabolism and Disposition November 1994, 22 (6) 928-936;

U

  1. Uchic, J T

    1. You have access
      The orally active renin inhibitor A-74273. In vivo and in vitro morpholine ring metabolism in rats, dogs, and humans.
      J F Denissen, B A Grabowski, M K Johnson, S A Boyd, J T Uchic, H Stein, S Cepa and P Hill
      Drug Metabolism and Disposition November 1994, 22 (6) 880-888;

V

  1. Vandenbranden, M

    1. You have access
      Relationships between the levels of cytochrome P4502C9 and its prototypic catalytic activities in human liver microsomes.
      S D Hall, M A Hamman, A E Rettie, L C Wienkers, W F Trager, M Vandenbranden and S A Wrighton
      Drug Metabolism and Disposition November 1994, 22 (6) 975-978;

W

  1. Watkins, P B

    1. You have access
      Interpatient heterogeneity in expression of CYP3A4 and CYP3A5 in small bowel. Lack of prediction by the erythromycin breath test.
      K S Lown, J C Kolars, K E Thummel, J L Barnett, K L Kunze, S A Wrighton and P B Watkins
      Drug Metabolism and Disposition November 1994, 22 (6) 947-955;
  2. Wienkers, L C

    1. You have access
      Relationships between the levels of cytochrome P4502C9 and its prototypic catalytic activities in human liver microsomes.
      S D Hall, M A Hamman, A E Rettie, L C Wienkers, W F Trager, M Vandenbranden and S A Wrighton
      Drug Metabolism and Disposition November 1994, 22 (6) 975-978;
  3. Wittfoht, W

    1. You have access
      Identification of 9,13-dicis-retinoic acid as a major plasma metabolite of 9-cis-retinoic acid and limited transfer of 9-cis-retinoic acid and 9,13-dicis-retinoic acid to the mouse and rat embryos.
      G Tzimas, J O Sass, W Wittfoht, M M Elmazar, K Ehlers and H Nau
      Drug Metabolism and Disposition November 1994, 22 (6) 928-936;
  4. Wrighton, S A

    1. You have access
      Interpatient heterogeneity in expression of CYP3A4 and CYP3A5 in small bowel. Lack of prediction by the erythromycin breath test.
      K S Lown, J C Kolars, K E Thummel, J L Barnett, K L Kunze, S A Wrighton and P B Watkins
      Drug Metabolism and Disposition November 1994, 22 (6) 947-955;
    2. You have access
      Relationships between the levels of cytochrome P4502C9 and its prototypic catalytic activities in human liver microsomes.
      S D Hall, M A Hamman, A E Rettie, L C Wienkers, W F Trager, M Vandenbranden and S A Wrighton
      Drug Metabolism and Disposition November 1994, 22 (6) 975-978;

X

  1. Xia, F

    1. You have access
      Propranolol disposition in the single-pass isolated, perfused rat liver in the presence and absence of insulin and glucagon.
      H A Semple and F Xia
      Drug Metabolism and Disposition November 1994, 22 (6) 822-826;

Z

  1. Zenser, T V

    1. You have access
      Glucuronidation of N-acetylbenzidine by human liver.
      S R Babu, V M Lakshmi, T V Zenser and B B Davis
      Drug Metabolism and Disposition November 1994, 22 (6) 922-927;
Back to top
PreviousNext

In this issue

Drug Metabolism and Disposition
Vol. 22, Issue 6
1 Nov 1994
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Back Matter (PDF)
  • Editorial Board (PDF)
  • Front Matter (PDF)
Sign up for alerts
  • Most Read
Loading
  • Cannabinoid Metabolites as CYP450 Inhibitors
  • Physiology of the Neonatal Gastrointestinal System
  • Pharmacokinetics and Disposition of Biologics
  • Switch from CAR to PXR in the Presence of EGF
  • Alternative P450 Splicing Redirects Human Drug Metabolism
More...
Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About DMD
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Journal of Pharmacology and Experimental Therapeutics
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-009X (Online)

Copyright © 2022 by the American Society for Pharmacology and Experimental Therapeutics